Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can early treatment stop vasculitis relapses? new study aims to find out

NCT ID NCT07451847

First seen Mar 07, 2026 · Last updated May 19, 2026 · Updated 8 times

Summary

This study looks at people with a type of blood vessel inflammation called ANCA-associated vasculitis. It compares two approaches when signs of the disease reappear in blood tests: giving the drug rituximab right away versus waiting for symptoms to appear. The goal is to see if early treatment can prevent relapses and reduce the need for more medication. About 70 adults who have been on maintenance rituximab for at least 18 months will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS (AAV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hôpital Cochin

    Paris, 75014, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.